1 October 2019

ReCognitION, a new 1.3 M€ European project under the leadership of Peter-Bram ‘t Hoen, Baziel van Engelen and Jeffrey Glennon, was kicked-off in Gent. ReCognitION is an acronym for Recognition and Validation of Druggable Targets from the response to Cognitive Behaviour Therapy in Myotonic Dystrophy type 1 patients from Integrated -Omics Networks. The project is built on the successful OPTIMISTIC clinical trial. The OPTIMISTIC trial showed a positive effect of lifestyle interventions on the social participation and physical activity of Myotonic Dystrophy patients. In ReCognitION, Radboudumc will work with partners in Gent, Paris, Prague and Ottawa to understand the molecular pathways underlying the response to cognitive behavioural therapy and to identify drugs targeting these pathways that may consolidate or reinforce the effect of cognitive behavioural therapy.

ReCognitION was funded by ZON-MW and similar national funding organisations in Belgium, France, the Czech Republic and Canada under the eRARE program.


 

Related news items


What does the shingles vaccine teach us about other vaccines? Investigating the role of trained immunity

27 January 2022

The vaccine for shingles, a condition that causes itching, pain, and blisters, is 90% effective, even in elderly. This is remarkable, since most vaccines offer less protection in elderly. Radboudumc is investigating why this vaccine works so well and how it might help us to develop better vaccines.

read more

RIMLS PhD retreat 2022 Register now

25 January 2022

This year, the 2-day RIMLS PhD retreat will be held on 14 & 15 July 2022 in the Koningshof, Veldhoven. We are aiming for a live event again!

read more

Most COVID-19 ICU survivors experience symptoms one year after ICU admission Publication in JAMA

25 January 2022

75% of the COVID-19 survivors who were treated in the Intensive Care Unit (ICU) experience physical, mental and/or cognitive problems one-year post ICU. This shows the large-scale MONITOR-IC study led by Radboudumc.

read more

Laurens Verscheijden awarded doctorate degree 'cum laude'

19 January 2022

Laurens Verscheijden of the Department of Pharmacology and Toxicology, defended his PhD thesis, entitled "Mechanistic models for the prediction of brain drug exposure and response in the paediatric population: A virtual child reaching maturation.

read more

Aerobe exercise has a positive effect on brain function in Parkinson's disease patients

18 January 2022

Radboudumc researchers have shown that the brain function of patients with Parkinson's disease improved with regular exercise, which seems to strengthen the connections between different brain areas, while inhibiting brain shrinkage.

read more